Your browser doesn't support javascript.
loading
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Harrington, Patrick; Dillon, Richard; Radia, Deepti; Rousselot, Philippe; McLornan, Donal P; Ong, Mark; Green, Anna; Verde, Alessandro; Hussain, Farzana; Raj, Kavita; Kordasti, Shahram; Harrison, Claire; De Lavallade, Hugues.
Afiliación
  • Harrington P; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Sciences, King's College London.
  • Dillon R; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK; Medical and Molecular Genetics, King's College London.
  • Radia D; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust.
  • Rousselot P; Service d'Hematologie, Centre Hospitalier de Versailles, Université de Versailles Paris-Saclay, UMR1184, CEA.
  • McLornan DP; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Sciences, King's College London.
  • Ong M; Department of Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust.
  • Green A; Department of Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust.
  • Verde A; Integrated Toxicology Laboratory, Synnovis, King's College Hospital NHS Foundation Trust.
  • Hussain F; Integrated Toxicology Laboratory, Synnovis, King's College Hospital NHS Foundation Trust.
  • Raj K; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust.
  • Kordasti S; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Sciences, King's College London.
  • Harrison C; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Sciences, King's College London.
  • De Lavallade H; Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Sciences, King's College London. h.delavallade@nhs.net.
Haematologica ; 108(6): 1555-1566, 2023 06 01.
Article en En | MEDLINE | ID: mdl-36700403
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Leucemia Mieloide de Fase Crónica Límite: Humans Idioma: En Revista: Haematologica Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Leucemia Mieloide de Fase Crónica Límite: Humans Idioma: En Revista: Haematologica Año: 2023 Tipo del documento: Article